RxDoctor Payments Data

Roland Bourgeois, MD

Cardiovascular Disease · Metairie, LANPI 1881678589

Payments from drug & device makers

$683in general payments, 2019–2025

Across 42 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$162
  • Johnson & Johnson$133
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$75
  • Amarin Pharma, Inc.$52
  • Abiomed$52
  • Boston Scientific$50
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$683 in reported general payments places this provider in the 20th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$85,811
Medicare patients
564
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban895$751,191
EntrestoSacubitril/Valsartan327$307,709
Repatha SureclickEvolocumab422$272,531
JardianceEmpagliflozin288$237,070
XareltoRivaroxaban146$142,990
Praluent PenAlirocumab95$48,502
FarxigaDapagliflozin Propanediol54$41,936
VascepaIcosapent Ethyl32$27,138
BrilintaTicagrelor37$27,051
Ezetimibe1,157$17,996
MultaqDronedarone Hcl14$17,211
Rosuvastatin Calcium1,098$13,564
NexlizetBempedoic Acid/Ezetimibe19$12,385
Metoprolol Succinate981$12,036
Atorvastatin Calcium880$7,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$751,191895 claims
NovartisEntresto$162$307,709327 claims
Boehringer IngelheimJardiance$45$237,070288 claims
Johnson & JohnsonXarelto$133$142,990146 claims
Sanofi-aventis U.S. LLCMultaq$12$17,21114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →